The biggest of big data is British data because the National Health Service is huge. As Europe's largest employer and the world's largest employer of professionally trained people, it has access to comprehensive data on more people than any other healthcare provider. The NHS, the UK government, and UK-based life sciences innovators are looking to leverage this leading position to build a new life sciences industry based on genomics.
In this system, corporations and the state work together to maximise profits for a few corporations, while limiting public choice and excluding innovative new entrants from the market who have different ideas and might offer real choice. In short, they see Britain's genomic and health data as a resource to be exploited.
Compare this to simply changing diet and exercise to improve the health of the population. Ben Rubin We believe this approach is a path to increased reliance on pharmaceuticals, with enormous associated costs, and little or no net benefit.
Unfortunately, weakened regulatory agencies are unable or unwilling to address these adverse drug development effects. Seeing ourselves as partners They are unable to focus on new life science industries and international pharmaceutical companies. Clear safety signals from our own data.
it was COVID-19 A key role in all this was that the “crisis” provided an avenue for the mass adoption of new, untried, and undertested products whose benefits were unlikely to outweigh their considerable risks. In the panic of 2020, all this didn’t matter, and their deployment was hailed as the savior of civilization.
Rubin believes civilization should find other paths, simpler, more reliable solutions, to result in a healthier population.
Ben Rubin's Blog Substack.
This interview should be considered alongside one conducted by UK Column with Dr Jobst Landgrebe and Professor Barry Smith about the limitations of artificial intelligence that are not fully understood.
In the interview, Rubin referred to Hedley Rees' article in the UK Column about the MHRA's disturbing plans to depersonalise medicines regulation, and to Professor Norman Fenton's response to a damning speech by MHRA CEO Dr June Raine (first brought to our attention by UK Column nursing correspondent Debi Evans), which saw the UK medicines regulator Not fit for purpose.
